APVO

Aptevo Therapeutics Inc. (APVO) - Q1 2026 10-Q Summary

Business Context and Reporting Period

This report covers the quarterly period ended March 31, 2026. Aptevo Therapeutics Inc. is a clinical-stage biotechnology company focused on developing novel immunotherapy candidates for cancer treatment. The company operates as a single segment focused on the discovery and development of oncology therapeutics using its ADAPTIR and ADAPTIR-FLEX platforms. Key clinical candidates include mipletamig (CD123xCD3 T cell engager for AML) and ALG.APV-527 (4-1BB/5T4 bispecific antibody).

Key Financial Metrics

Note: The company reported no product revenue. Net loss per share was $(6.41) for Q1 2026 compared to $(1,581.81) for Q1 2025, reflecting a significant increase in weighted average shares outstanding due to reverse stock splits and new issuances.

Material Changes vs. Prior Period

• Operating Expenses: Total operating expenses increased to $6.837 million in Q1 2026 from $6.480 million in Q1 2025. Research and Development (R&D) expenses rose to $3.924 million (from $3.633 million), driven by increased costs for the mipletamig program and employee costs, partially offset by lower expenses for ALG.APV-527 following the conclusion of its dose escalation trial.
• Liquidity Position: Cash and cash equivalents decreased by $7.094 million during the quarter to $14.525 million. This burn rate was partially mitigated by financing activities.
• Financing Activities: The company raised approximately $0.871 million in net proceeds from the issuance of common stock under Standby Equity Purchase Agreements (SEPAs) with Yorkville. In the subsequent events period (post-March 31), an additional $0.2 million was raised.
• Equity Structure: A 1-for-18 reverse stock split was effected on December 29, 2025. As of March 31, 2026, there were 1,203,753 shares of common stock issued and outstanding.

Guidance, Outlook, and Risks

• Going Concern Warning: Management has concluded that there is substantial doubt about the company's ability to continue as a going concern for the one-year period following the issuance of these financial statements. The company has suffered recurring losses and negative cash flows and will require additional funding to support operations and capital needs.
• Clinical Outlook: The RAINIER trial for mipletamig is on track for completion and Phase 2 dose selection by year-end 2026. Recent data showed an 87% clinical benefit rate and 81% CR/CRi rate in frontline AML patients, with no observed cytokine release syndrome (CRS).
• Capital Resources: The company has access to approximately $67.2 million in remaining capacity under two SEPAs with Yorkville ($8.0 million under the First SEPA and $59.4 million under the Second SEPA). The At-The-Market (ATM) facility currently has no remaining availability due to public float limitations, with capacity expected to return after October 2026.
• Risk Factors: Key risks include the inability to raise additional capital on acceptable terms, potential delisting from Nasdaq if stockholders' equity or bid price requirements are not met, and the inherent risks of clinical trial failure. The company also faces macroeconomic risks including inflation and geopolitical instability.

Investor Verification Checklist

• Going Concern Status: Verify the company's immediate plan to secure funding beyond the current cash balance of $14.5 million and the $67.2 million SEPA capacity.
• Nasdaq Compliance: Monitor stock price and stockholders' equity levels to ensure continued compliance with Nasdaq listing rules (minimum $1.00 bid price and $2.5 million stockholders' equity).
• SEPA Utilization: Track the utilization of the Yorkville SEPAs and the timeline for the ATM facility to regain availability in October 2026.
• Clinical Milestones: Confirm the timeline for the RAINIER trial Phase 2 dose selection and the potential for future milestone payments from Medexus regarding IXINITY.
• Dilution Impact: Assess the impact of potential future equity issuances and the exercise of outstanding warrants (approx. 677,000 warrants) on shareholder dilution.